Tag: Cteph

First approved by the FDA in 2013, Adempas (riociguat) is a unique medication that was the first in a new class of drugs for pulmonary hypertension. It is prescribed to treat two specific types of pulmonary hypertension in adults, and for pediatric patients of a certain weight with pulmonary arterial hypertension (PAH).

Adempas (riociguat) is a medication prescribed for individuals with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). These are typically progressive conditions requiring ongoing management rather than short-term cures. Understanding how long should Adempas be taken involves recognizing its role in managing these conditions over the long term.

According to results from the CHEST-1 and PATENT-1 trials, Adempas (riociguat) has demonstrated significant effectiveness by improving key markers of pulmonary hypertension, such as exercise capacity and overall disease severity. This article explores the details of **how effective is Adempas** and what the clinical data and patient experiences suggest.

Adempas (riociguat) was the first member of a new drug class known as soluble guanylate cyclase (sGC) stimulators to receive FDA approval in 2013. This medication is used to treat adults with two specific types of high blood pressure in the lungs: chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).

In a pivotal clinical trial for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), patients taking riociguat showed a mean increase of 39 meters in the six-minute walk distance (6MWD), compared to a 6-meter decrease in the placebo group. This article details how effective is riociguat based on extensive clinical data.

An estimated 1% of the global population has some form of pulmonary hypertension [1.11.2]. For those with specific types like CTEPH and PAH, a key question is: **what does Adempas do?** This medication helps relax and widen blood vessels in the lungs, easing the heart's workload [1.2.1, 1.3.4].